Tech2Transfer

Tech2Transfer enters the market as a specialized decision-support tool aimed at a persistent bottleneck in the innovation ecosystem: the gap between scientific discovery and commercial application. Its core proposition is to use large language models to automatically analyze scientific papers and assess both technology readiness and market potential, effectively compressing what is often months of manual due diligence into a structured, data-driven overview. This is not a general-purpose research assistant; it is a targeted instrument for stakeholders who need to evaluate whether a piece of research is worth pursuing, funding, or partnering on. The platform’s standout strength lies in combining two critical assessments—technical maturity and commercial viability—within a single workflow, while adding patent landscape analysis to contextualize competitive positioning. For researchers, this means a faster path from lab results to investor pitch; for investors, a systematic filter for deep-tech opportunities; for corporate R&D teams, a tool to scan for external innovations that align with strategic gaps. However, the tool’s current scope is limited to scientific papers, which may exclude valuable signals from patents, technical reports, or preprints. The promised Intelligent Matchmaking feature, slated for Phase 2, remains unavailable, so the platform currently functions as an assessment engine rather than a full matchmaking marketplace. Pricing is undisclosed, making cost-benefit analysis difficult for potential buyers. In practice, Tech2Transfer fits best into workflows where the volume of research to screen is high and the need for speed outweighs the desire for deep, manual analysis. Its automated readiness scoring, while efficient, operates as something of a black box—users must trust the LLM’s interpretation of technology readiness levels without full transparency into the scoring criteria. Similarly, market potential evaluations likely rely on comparable technology benchmarks rather than custom primary research, so projections should be treated as directional indicators. For a serious buyer, the platform is most valuable as a triage tool: it can flag which papers warrant deeper investigation, but it should not replace expert judgment in final decisions. As the tool matures and adds matchmaking capabilities, its utility could expand significantly, but in its current form, it serves a narrow but real need for those who need to move quickly from research to commercialization decisions.